SARS-CoV-2 vaccines: anamnestic response in previously infected recipients

Purushotham, Jyothi N.; Doremalen, Neeltje van; Munster, Vincent J.

doi:10.1038/s41422-021-00516-7

Cited by 16 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients who had COVID‐19, their prior infections will serve as a priming dose of antigen; the first vaccination dose then, in effect, becomes the booster shot. 38 Additionally, several studies make note that the second dose in this situation provides virtually no additional boost to antibody levels. 29 , 38 , 39 , 40 , 41 , 42 , 43 , 44 These findings may suggest that people who had COVID‐19 can benefit from one just dose of CoronaVac.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamics of antibody response to CoronaVac vaccine

Fonseca

Souza

Araújo

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

CoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long-term evidence on post-vaccination antibody persistence. This study evaluated the antibody response to SARS-CoV-2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months postvaccination (6mA2D) with CoronaVac. The seropositivity was 88% at 1D, increasing to 99.8% at 2D, but decreasing to 97.9% at 6mA2D, which was also observed at the analyzed antibody levels. Interestingly, the levels in females were higher than males, and we found a positive correlation with previous SARS-CoV-2 infection. Participants with comorbidities had lower levels suggesting the need to monitor for a potential booster dose. Our findings suggest that CoronaVac induced a robust antibody response that wanes significantly over time. Further longitudinal studies are needed to identify whether the antibodies will decline or plateau at a lower level.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 38 Additionally, several studies make note that the second dose in this situation provides virtually no additional boost to antibody levels. 29 , 38 , 39 , 40 , 41 , 42 , 43 , 44 These findings may suggest that people who had COVID‐19 can benefit from one just dose of CoronaVac.…”

Section: Discussionmentioning

confidence: 99%

Dynamics of antibody response to CoronaVac vaccine

Fonseca

Souza

Araújo

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…It has been observed that memory B cells continue accumulating somatic mutations over 12 months in germinal centers in individuals who have recovered from COVID-19 13,25 . Those mutations accumulated long after infection are, indeed, though accountable for the high potency in serum neutralization activity of the convalescent vaccinee cohorts against VOCs 12 . Although the study performed by Goel et al it was not found any change in the levels of SHMs in memory B cell clones from convalescent individuals as a response to vaccination 17 , naïve vaccinees also would enter into this memory B cell maturation after antigen exposure (vaccination), if analyzed after long spans 12 .…”

mentioning

confidence: 99%

“…Acquiring knowledge on the immune response dynamics that convalescent individuals who are subsequently vaccinated develop is essential. The deep understanding of this "hybrid immunity" will allow the design of appropriate vaccination regimes for the vast population of previously infected individuals 12 .…”

mentioning

confidence: 99%

“…Relevantly, such protective immunity suffers a considerable weakening in the face of current circulating SARS-CoV-2 variants of concern (VOCs) -i.e., B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) -when compared with the wild-type Wuhan-Hu-1 variant 4, [14][15][16] . As identified by previous works, multiple spike (S) protein mutations in VOCs explain their ability to escape neutralization antibody activity partially, making the acquired natural protective immunology less effective 7,12 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hybrid immunity: the immune response of COVID-19 survivors to vaccination

Gancino

Vispo

2021

View full text Add to dashboard Cite

Hybrid immunity can become a turning-point opportunity to defeat the infection in context with the current pandemic scenario. Adopting policies aligned with the data mentioned above may be particularly beneficial for regions like Latin America. While this region shares only ~5% of the world population, it accumulates +16% of the ~200 million COVID-19 total cases, so far reported1. Acknowledging the reduced diagnostic capabilities of these countries, this entire area is probably one of the most affected globally, leading to one of the more numerous populations of convalescent people. From both an economic and pharmacological perspective, applying a one-dose regime of pertinent vaccines to convalescent individuals is sustainable5. As COVID-19 survivors may need just one vaccination to achieve high levels of protective immunity, massive antibody screening for SARS-CoV-2 spike antibodies could help prioritize and free up doses, optimize vaccine supply efficiency, and surpass problems linked to the current vaccine manufacturing bottleneck

show abstract